Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $15.0 million.

  • Cardiff Oncology's Total Liabilities rose 1100.41% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 1100.41%. This contributed to the annual value of $14.2 million for FY2024, which is 1969.24% up from last year.
  • According to the latest figures from Q3 2025, Cardiff Oncology's Total Liabilities is $15.0 million, which was up 1100.41% from $17.1 million recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's Total Liabilities ranged from a high of $17.1 million in Q2 2025 and a low of $4.8 million during Q1 2021
  • Moreover, its 5-year median value for Total Liabilities was $10.8 million (2022), whereas its average is $11.1 million.
  • As far as peak fluctuations go, Cardiff Oncology's Total Liabilities plummeted by 1616.97% in 2021, and later surged by 12398.26% in 2022.
  • Over the past 5 years, Cardiff Oncology's Total Liabilities (Quarter) stood at $9.1 million in 2021, then grew by 7.9% to $9.8 million in 2022, then grew by 20.82% to $11.9 million in 2023, then increased by 19.69% to $14.2 million in 2024, then increased by 5.26% to $15.0 million in 2025.
  • Its Total Liabilities was $15.0 million in Q3 2025, compared to $17.1 million in Q2 2025 and $13.9 million in Q1 2025.